SCL Science KRX:246960KOSDAQ
SCL사이언스 · Korean news coverage and regulatory filings, organized.
In Q2 2026, SCL Science reported revenue of ₩7.6bn, up 68.9% year on year, and operating profit of ₩406m. SCL Science (SCL사이언스) appeared in 11 Korean news articles and 1 DART filing over the past seven days. Coverage peaked on Oct 20 with 7 articles. The most common catalyst was tech & capacity (1). It was most often mentioned alongside GFC Life Science, Y-Biologics and Genolution.
Filing signals Turnaround M&A / stake deal Screener
SCL Science quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩7.6bn | +68.9% | ₩406m margin 5.3% | −₩130m |
| Q1 2026 | ₩7.7bn | +237.9% | −₩648m margin −8.5% | −₩994m |
| Q4 2025 derived | ₩8.3bn | +419.2% | −₩848m margin −10.2% | −₩2.6bn |
| Q3 2025 | ₩7.0bn | +594.8% | ₩169m margin 2.4% | −₩122m |
| Q2 2025 | ₩4.5bn | +347.1% | −₩1.4bn margin −30.5% | ₩207m |
| Q1 2025 | ₩2.3bn | +100.0% | −₩1.3bn margin −59.5% | −₩1.6bn |
| Q4 2024 derived | ₩1.6bn | +152.3% | −₩1.4bn margin −85.5% | −₩1.3bn |
| Q3 2024 | ₩1.0bn | +248.7% | −₩780m margin −77.9% | −₩822m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
SCL Science top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
- 6
Latest SCL Science news Korean headlines
-
SCL사이언스, 파키스탄 현지 업체와 지혈 패드 '이노씰' 유통 MOU 체결
1 more on this story · 1 outlets
- SCL사이언스, 이노씰 파키스탄 유통 MOU 체결메디포뉴스 · Oct 26 12:34
-
SCL사이언스, 베트남 후에중앙병원과 MOU 체결
1 more on this story · 1 outlets
- SCL사이언스, 베트남 후에중앙병원과 MOU 체결국제뉴스 · Oct 20 15:52
-
SCL사이언스, '이노씰 플러스 DL' 서남권 빅3 대학병원 치료재료 코드 등록
1 more on this story · 1 outlets
- SCL사이언스, ‘이노씰 플러스 DL’ 대학병원 3곳 코드 확보메디포뉴스 · Oct 1 14:28
-
SCL사이언스, AI 암백신 2028년 임상 진입
2 more on this story · 1 outlets
- SCL사이언스, AI 암백신 임상 시동…2028년 첫 투여·자회사 합병 검토이데일리 · Sep 30 11:02
- SCL사이언스, AI 암백신 임상 시동…2028년 첫 투여·자회사 합병 검토이데일리 · Sep 30 11:03
-
SCL사이언스, AI 암백신 28년 첫 환자 투여 목표…네오젠로직 합병 검토
1 more on this story · 1 outlets
- SCL사이언스, AI 암백신 2028년 첫 환자 투여 목표…네오젠로직 합병도 검토한국경제 · Sep 30 13:31